Revvity expands access to base editing technology with aim to accelerate discovery to cure

Launch of Pin-pointTM base editing reagents improves access to new-generation editing technology Access to the Pin-point system now bridges discovery, preclinical and clinical with the same technology platform Reagent launch puts clinica

Revvity unveils next-generation preclinical imaging technologies to help scientists drive breakthrough discoveries

WALTHAM, Mass., Revvity, Inc. debuts its enhanced imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three systems.

Revvity establishes Scientific Centre of Excellence for Genomic Insight in Cambridge

Global health science solutions company Revvity, Inc., has announced the establishment of a Scientific Centre of Excellence in Cambridge, UK. Focused on driving genomic insights to accelerate therapeutic discovery, Revvity’s Scientific Centre of Excellence supports the Company’s fundamental commitment to expanding boundaries in pursuit of a better future for human health.

PerkinElmer’s Horizon Discovery CHOSOURCE platform expands

Existing CHO platform, featuring low cost and no royalty or licence tie-ins, expands with new cell line to help develop biotherapeutics with increased potency and longevity and decreased side effects.

Horizon Discovery extends gene modulation portfolio

CRISPRi innovations provide expanded experimental options and flexibility for researchers, facilitating disease and drug research.

Horizon Discovery licenses CHOSOURCE to Sanyou Biopharmaceuticals Co

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, announced that it has granted two commercial licences for its cGMP-compliant CHOSOURCE™ platform to Sanyou Biopharmaceuticals Co., Ltd.